- Home
- SPFI vs QURE Comparison
SPFI vs QURE Comparison
Compare SPFI & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | QURE |
|---|---|---|
| Founded | 1941 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.4M | 663.4M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SPFI | QURE |
|---|---|---|
| Price | $41.25 | $14.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $44.00 | ★ $44.92 |
| AVG Volume (30 Days) | 84.0K | ★ 4.6M |
| Earning Date | 04-23-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | 17.81 | ★ 29.67 |
| EPS | ★ 3.44 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $22.65 | $126.12 |
| Revenue Next Year | $9.40 | $210.54 |
| P/E Ratio | $12.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.01 | $7.76 |
| 52 Week High | $44.00 | $71.50 |
Technical Indicators
Market Signals| Indicator | SPFI | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 42.74 |
| Support Level | $39.49 | $13.35 |
| Resistance Level | $41.91 | $15.98 |
| Average True Range (ATR) | 1.05 | 1.43 |
| MACD | 0.08 | 0.28 |
| Stochastic Oscillator | 62.28 | 12.52 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.